Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wedekind, S. Neuer Therapiestandard bei MRD-negativer B-ALL: Konsolidierung mit Blinatumomab. Im Fokus Onkologie 26, 28–29 (2023). https://doi.org/10.1007/s15015-023-3060-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15015-023-3060-2